explore -WSS

explore

author：entertainment 2025-10-01 01:49:46 - browse：43516

A yellow number 3 with an eye is surrounded by smaller, black number 3s on a pink background — 3 to watch coverage from STAT — Christine Kao/STAT

Health tech hopefuls might once have been used to a wealth of job options, especially in the pandemic’s early stages when investors pumped record-breaking dollar amounts into an unprecedented number of ventures.

That glut of opportunities meant workers could bargain harder for better job offers, demanding perks and flexibilities like permanent remote work or expensive fertility benefits. But belt-tightening and market consolidation across health tech companies have tipped the scales back in favor of employers, who are continuing to hire — for a seemingly dwindling number of positions.

It might feel like a downturn, although it’s possible that the industry is simply easing back into its pre-pandemic normal, before the massive infusion of venture dollars and the hype surrounding virtual care, said Brookings Institution research fellow Niam Yaraghi, who studies health care employment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： FDA approves world's first CRISPR

explore

WSS

Patients' immediate access to test results puts radiologists in a bind

Streamlined flu vaccines recommended by FDA advisory panel

Roche to buy Carmot Therapeutics, developer of obesity drugs

Immune cells and nerve overgrowth may explain recurring UTI pain

State of the Union pitch: Bigger Medicare drug price negotiations

$1 billion proposal to grow Boston, Massachusetts biotech

focus

explore

explore

The high cost of giving birth even with insurance

First over

Alkermes shareholders re

Immune cells and nerve overgrowth may explain recurring UTI pain

Walensky prepares to leave CDC — and Congress — behind

Medicare drug price negotiation hearing pits pharma v Biden admin

Hepatitis C has a cure — but many Americans still lack access to it

FDA approves world's first CRISPR

Drug repurposing or repositioning? The language matters

The public health thinking behind the CDC’s new Covid guidance

focus

Medicare drug price negotiation hearing pits pharma v Biden admin

Fetal cell organoids grown from amniotic fluid, study finds

Medicare drug price negotiation continues, as pharma counteroffers

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Ancient Greek ideas underpin modern concepts of pregnancy

Why sickle cell disease is getting the first CRISPR treatment

hotspot

entertainment

leisure time

hotspot